A federal judge has approved a major settlement requiring the Sackler family, owners of OxyContin maker Purdue Pharma, to pay up to $7 billion. The money will support treatment, recovery, and prevention programs across the United States as the nation continues to struggle with the opioid crisis.
Since 1999, opioids have been linked to about 900,000 deaths. Addiction has damaged families, strained healthcare systems, and affected entire communities. Public health experts say this settlement will provide critical resources for people who need long-term help and for the systems that support them.
Funds Will Support Treatment, Recovery, and Child Health Programs
Most of the money will go to states, local governments, and tribal nations. The funding is expected to strengthen major public health efforts, including:
- Expanding addiction treatment centers
- Improving long-term recovery and mental-health services
- Increasing access to overdose-reversal medications like naloxone
- Supporting care for pregnant women with opioid use disorder
- Improving treatment for infants born with withdrawal symptoms
About $850 million will go directly to affected individuals, including people struggling with addiction and children harmed by prenatal opioid exposure.
People who can show they received OxyContin prescriptions may receive about $8,000 to $16,000, depending on the length of treatment and the number of eligible applicants. Payments are expected to begin next year.
Improving Access to Addiction Treatment
Many communities have long faced a shortage of affordable addiction services. Treatment can be expensive, and support programs often lack stable funding. This settlement may help change that by allowing:
- More clinics to accept patients regardless of income
- Families to access counseling and social services
- Doctors to receive training in addiction medicine
- Public health teams to better track and prevent overdoses
Experts say reliable funding is essential because opioid addiction behaves like a chronic illness. People often need ongoing care, not short-term treatment.
Purdue Will Be Replaced With a Public-Benefit Company
Purdue Pharma will be reorganized into a new company called Knoa Pharma. It will be overseen by a board chosen by the states and will operate with a public-health mission instead of a profit-driven one.
The company will also release a large collection of internal documents. Researchers and public health groups expect these materials to offer new insights into how opioids were marketed and how the crisis grew.
The Sackler family will also stop seeking naming rights in exchange for donations, a practice many institutions have already rejected.
A Turning Point in a Long Health Crisis
Purdue filed for bankruptcy in 2019 after thousands of lawsuits linked OxyContin to widespread addiction and overdose deaths. After years of debate and revisions, the new settlement may mark a key moment in the nation’s health response to the opioid epidemic.
While a few individuals still plan to challenge the agreement, most groups support it. Many believe the settlement will provide crucial resources to communities working to save lives and help people recover.
Related topics
New Online Tool Helps Young Adults Plan Long-Term Heart Health
ACA Health Marketplace Premiums to Rise 20% Nationwide in 2026
Lilly Medicine Company Secures Approval For New Alzheimer’s Treatment
